Physician profile
Freya J Silverstein
NPI 1669467460
$1,429.01
in general payments reported to CMS, 2019-2025
14 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $198 · 2021: $179 · 2022: $66.97 · 2023: $53.63 · 2024: $299 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.28 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $298.31 | 2019-2025 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $241.95 | 2019-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $176.96 | 2019-2024 | Jynarque |
| Fresenius USA Marketing, INC. | $164.73 | 2019-2025 | Velphoro, Velphoro |
| La Jolla Pharmaceutical Company | $122.49 | 2020 | |
| Akebia Therapeutics INC | $100.95 | 2019-2024 | Vafseo |
| Mallinckrodt Enterprises LLC | $61.12 | 2019 | |
| Vifor Pharma, INC. | $57.56 | 2019-2020 | |
| Travere Therapeutics, INC. | $56.24 | 2023-2025 | Filspari |
| Shire North American Group INC | $43.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.32 | 2022 | |
| Alexion Pharmaceuticals, INC. | $30.83 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $20.39 | 2019 | |
| Horizon Therapeutics Plc | $15.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freya Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.